Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 11
Submit an article Journal homepage
562
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

Mathew A. CherianDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Raoul TibesDivision of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA;
,
Feng GaoDepartment of Surgery, Division of Public Health Sciences, School of Medicine, Washington University, St. Louis, MO, USA
,
Theresa FletcherDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Mark FialaDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Geoffrey L. UyDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Peter WesterveltDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Meagan A. JacobyDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Amanda F. CashenDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
Keith Stockerl-GoldsteinDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
,
John F. DiPersioDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA;
&
Ravi VijDepartment of Medicine, Division of Oncology, School of Medicine, Washington University, St. Louis, MO, USA; Correspondence[email protected]
 show all
Pages 2535-2540 | Received 19 Oct 2015, Accepted 26 Mar 2016, Published online: 27 Apr 2016

References

  • Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. JNCCN. 2011;9:57–63.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322–3327.
  • Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014;106:djt440.
  • Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28:1657–1665.
  • List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
  • List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–557.
  • Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117:1828–1833.
  • Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
  • Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015;33:57–66.
  • Kantarjian H, Garcia-Manero G, O’Brien S, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28:285–291.
  • Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099–1110
  • Tibes R, Al-Kali A, Oliver GR, et al. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. J Hematol Oncol 2015;8:114.
  • Raza A, Galili N, Smith SE, et al. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 2012;118:2138–2147.
  • Garcia-Manero G, Khoury HJ, Jabbour E, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015;21:985–994.
  • Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113:3947–3952.
  • Harada H, Watanabe M, Suzuki K, et al. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol. 2009;90:353–360.
  • Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymph Myel Leuk. 2012;12:341–344.
  • Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.
  • Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28:4919–4925.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.